CRISPR Therapeutics AG ↗
Biotechnology: Biological Products (No Diagnostic Substances) company
Key Metrics of CRISPR Therapeutics AG
Revenue$371M▲ 30,885.5% YoYFY 2023
Operating income−$223M▲ 66.9% YoY
Net profit−$154M▲ 76.4% YoY
Shareholders' equity$1.9B
Market cap$5.0BCRSP · $51.42
Competitors10identified
About CRISPR Therapeutics AG
Sectors
Company details
- Website
- crisprtx.com
- Founded
- 2016
- Listed
- Nasdaq: CRSP (since 2016)
Operational Areas of CRISPR Therapeutics AG
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameCRISPR Therapeutics AG
TickerCRSP
ExchangeNasdaq
CountrySwitzerland
SEC CIK0001674416
Listed since2016
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Websitehttp://www.crisprtx.com
US market & SEC filings
CRSP · Nasdaq · SEC CIK 0001674416
Last price · 02 Nov 2026
$51.42
−5.23%
Market cap$5.0B
P/E—On FY 2023 diluted EPS
Volume1,167,712
SectorHealth CareBiotechnology: Biological Products (No Diagnostic Substances)
Country · IPOSwitzerlandListed 2016
CRSP share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered officeZug
GSTIN—
Email—
Websitehttp://www.crisprtx.com
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of CRISPR Therapeutics AG
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
biotechnology industry
Filings
No filings on record yet.